NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

No, Donald Trump was not the focus of attention this week, even though the US president invited people to a parade to ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...